Lunai Bioworks (LNAI)

• Market cap: $22.7M
• 1 day: -1.53%
• 5 days: -6.64%
• 1 month: -24.74%
• 3 months: -25.32%
• 6 months: -72.18%
• Year to date: -87.28%
• 1 year: -89.3%
• 5 years: -96.71%
• 10 years: -98.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Employees: 29